Roivant Sciences Ltd. filings document material events for a Nasdaq-listed Bermuda biopharmaceutical company with common shares registered under the ticker ROIV. The company’s recent Form 8-K disclosures cover quarterly financial results, preliminary liquidity information, share repurchases, Regulation FD updates and exhibits tied to clinical programs at subsidiaries such as Priovant Therapeutics.
Its filings also record material definitive agreements and amendments, including the Genevant Sciences settlement agreement involving lipid nanoparticle delivery technology, as well as shareholder voting results from the annual general meeting. Governance disclosures include director elections, auditor ratification and other proxy-related voting matters, while clinical exhibits describe programs such as brepocitinib in autoimmune and inflammatory diseases.
Epperly Melissa B, reported acquisition or exercise transactions in this Form 4 filing.
Roivant Sciences Ltd. director Melissa B. Epperly received a grant of 670 Common Shares as equity compensation. The award was made under the company’s Non-Employee Director Compensation Plan and was fully vested on the grant date. Following this grant, she directly holds 16,474 Common Shares.
Roivant Sciences Ltd. director James C. Momtazee reported routine equity compensation activity. He received 469 Common Shares as an award under Roivant’s Non-Employee Director Compensation Plan, which were fully vested on the grant date. To cover related tax withholding obligations, 94 previously granted Common Shares were net-settled back to the company. After these transactions, he directly holds 109,405 Common Shares. These entries reflect compensation and tax withholding mechanics rather than open-market buying or selling.
Roivant Sciences CEO Matthew Gline reported an open-market sale of 289,774 common shares at a weighted average price of $29.16 per share. According to the filing, the trades occurred across multiple transactions between $28.98 and $29.36. After these sales, he directly owns 16,736,116 common shares.
Roivant Sciences Ltd. reported a Form 144 notice for the proposed sale of 200,000 common shares to be sold on 04/20/2026 (method: Options Exercise, grant date 04/20/2022). The filing also shows recent dispositions: 200,000 shares on 02/13/2026, 7,051 shares on 02/20/2026, and 200,000 shares on 04/20/2026, with proceeds listed for each transaction.
Rockefeller Financial LLC submitted an amended Form 144 (144/A) reporting proposed or previously executed sales of common stock of ROIV. The filing lists grant‑related securities (a CVAR grant and RSU grant) with grant dates and sale activity dated 03/30/2026 and 03/31/2026.
Rockefeller Financial LLC and related parties reported proposed and recent sales of Common Stock. The excerpt lists proposed dispositions of 43,493 shares (CVAR grant, dated 03/30/2026) and 246,281 RSUs (grant dated 07/26/2024) with settlement dates in late March 2026. It also reports sales by Matthew Gline on 03/30/2026 of 53,826 shares for $1,421,544.66 and 304,684 shares for $8,439,746.80.
Roivant Sciences Ltd. Chief Accounting Officer Jennifer Humes reported an open-market sale of 13,538 Common Shares of Roivant Sciences on April 8, 2026. The weighted average sale price was $28.37 per share, with individual trades executed between $28.36 and $28.38. After this transaction, she directly holds 84,191 Common Shares.
Roivant Sciences Ltd. reported that President and Vant Chair Frank Torti had 160,035 common shares withheld on March 31, 2026 to cover tax obligations tied to previously granted RSUs. The issuer net settled these RSUs to satisfy applicable tax withholding, and Torti now directly holds 13,576,512 common shares.
Roivant Sciences Ltd. reported preliminary unaudited consolidated cash, cash equivalents and marketable securities of approximately $4.3 billion as of March 31, 2026. The company repurchased 3,956,362 common shares during the quarter for about $109.7 million, excluding fees and commissions.
Roivant announced a new seamless Phase 2b/3 trial of brepocitinib in lichen planopilaris, adding a fourth late-stage indication alongside dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis. The FDA granted Priority Review to brepocitinib’s NDA in dermatomyositis, with a PDUFA target action date in Q3 2026.
The company also reported topline results from Immunovant’s two Phase 3 studies of batoclimab in thyroid eye disease, which did not meet the primary endpoint of ≥2mm proptosis responder rate at Week 24. Safety was consistent with prior data, and Immunovant plans to continue developing FcRn blocker IMVT-1402, including potentially registrational Graves’ disease studies with topline data expected in calendar year 2027.